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Abstract
BACKGROUND
FOLFIRINOX and gemcitabine plus nab-paclitaxel (Gem + nabPTX) were
recently introduced for metastatic pancreatic cancer treatment. However, studies
that compared these two regimens and studies in Asian populations are lacking.
AIM
To compare the treatment outcomes of FOLFIRINOX and Gem + nabPTX
regimen for metastatic pancreatic cancer treatment in Korean population.
METHODS
Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX
(n = 86) or Gem + nabPTX (n = 81) as the first-line since January 2015 were
identified using the Severance Hospital Pancreatic Cancer Cohort Registry.
Treatment efficacy, treatment-related adverse events and economic aspects were
compared.
RESULTS
Patients in the FOLFIRINOX group were significantly younger (54 vs 65 years; P
< 0.001) and had better performance statuses at diagnosis. The median overall
survival (10.7 vs 12.1 mo; P = 0.157), progression-free survival (8.0 vs 8.4 mo; P =
0.134), and objective response rates (33.7% vs 46.9%; P = 0.067) were not
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significantly different when compared with Gem + nabPTX group. Grade ≥ 3
neutropenia and gastrointestinal adverse events were more common in the
FOLFIRINOX group. The drug costs of both regimens were similar.
CONCLUSION
Treatment efficacy and economic burdens were comparable between the two
regimens. But, the details of adverse event were different. Gem + nabPTX
regimen might be considered preferentially in certain conditions.
Key words: Pancreatic cancer; Chemotherapy; FOLFIRINOX; Gemcitabine; Nab-
paclitaxel; Survival
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Both FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy
are widely used as a treatment of choice in patients with metastatic pancreatic cancer.
However, the treatment choice and sequence are not firmly established. In addition,
researches on Asian populations in this regard are scarce. In the present study, we
compared the treatment efficacy, safety, and economic aspects of FOLFIRINOX and
gemcitabine plus nab-paclitaxel combination therapy. We believe that this study can help
physicians and patients to select appropriate regimens while avoiding and preventing
unnecessary complications.
Citation: Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, An C,
Park MS, Bang S. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic





Pancreatic cancer demonstrates a very poor prognosis and is one of the main causes of
cancer-related death worldwide[1,2]. While the treatment outcomes of other cancers
have gradually improved, progress in the treatment outcomes of metastatic pancreatic
cancer has remained stagnant[3]. Since the late 1990s, several efforts have been made to
treat  metastatic  pancreatic  cancer[4-6].  Recently,  two  effective  regimens  were
introduced through large-scale clinical trials.
The FOLFIRINOX regimen, which consists of 5-fluorouracil (5-FU), leucovorin,
oxaliplatin, and irinotecan, was introduced by the PRODIGE4/ACCORD11 trial[7]. In
this clinical trial, FOLFIRINOX yielded superior survival rates when compared to
gemcitabine monotherapy. Another randomized phase III trial, MPACT, showed that
a  combination  of  gemcitabine  and  nab-paclitaxel  (Gem  +  nabPTX)  yielded  a
statistically  significant  survival  benefit  and response  rate  when compared with
gemcitabine monotherapy[8]. As a result, these two regimens are recommended as the
first-line therapy for metastatic pancreatic cancer[9,10].
However, there are two possible impediments when treating patients in a clinical
setting. The first is the treatment choice and sequence between the two standard
regimens. There is a lack of data regarding a direct comparison of the two regimens in
terms of the treatment outcome. In addition, reliable guidelines that help to select the
appropriate regimen according to each patient are lacking. The second impediment
concerns  ethnic  differences  between  western  and  east-Asian  populations.  Even
though we reported the efficacy and adverse events of Gem + nabPTX in Korean
population were similar to the western population, there are still lack of evidences for
supporting  the  results  of  MPACT  trial  in  Asian  countries [11 ].  In  terms  of
pharmacoethnicity, an understanding of the differences in treatment response and
adverse events according to ethnicity helps to improve chemotherapeutic tolerability
and effectiveness[12].
Therefore,  the  purpose  of  this  study was  to  compare  the  efficacy,  safety,  and
economic aspects of FOLFIRINOX and Gem + nabPTX in the treatment of metastatic
pancreatic cancer in Korean population.
WJGO https://www.wjgnet.com February 15, 2020 Volume 12 Issue 2




Patients  with  metastatic  or  recurrent  pancreatic  cancer  who  were  treated  with
FOLFIRINOX  or  Gem  +  nabPTX  since  January  2015  were  identified  using  the
Severance Hospital  Pancreatic  Cancer  Cohort  Registry,  which is  a  prospectively
collected database of pancreatic cancer patients who received anticancer therapy at
Severance Hospital since 2015. During the study period, a total of 924 patients were
registered in the cohort registry.
The inclusion criteria were as follows:  (1)  ≥ 18 years of  age;  (2)  Pathologically
confirmed  metastatic  or  recurred  pancreatic  adenocarcinoma;  (3)  At  least  one
measurable or evaluable lesion according to the Response Evaluation Criteria in Solid
Tumors (RECIST), version 1.1[13]; (4) Eastern Cooperative Oncology Group (ECOG)
performance status ≤ 2; (5) No prior anti-tumor treatment for metastatic or recurred
pancreatic adenocarcinoma; and (6) Adequate organ function (absolute neutrophil
count ≥ 1.5 × 109/L, serum creatinine < 1.5 mg/dL, or calculated creatinine clearance ≥
60 mL/min per the Cockcroft and Gault formula) before chemotherapy.
Finally, 167 patients who met the enrolment criteria were identified as eligible
patients.  This  study  was  approved  by  the  Yonsei  University  Health  System
Institutional  Review  Board  (Approval  number:  4-2015-1058)  and  conducted  in
accordance  with  the  principles  set  forth  in  the  Declaration  of  Helsinki.  Written
informed consent was obtained from all patients.
Treatment schedule and response evaluation
In  patients  who  received  the  FOLFIRINOX  regimen,  oxaliplatin  (85  mg/m2),
leucovorin (400 mg/m2), and irinotecan (180 mg/m2) were delivered via intravenous
infusion, which was followed by 400 mg/m2 (bolus) and 2400 mg/m2 (continuous
intravenous infusion over a 46-h period) of 5-FU administered every 2 wk. Patients
treated with Gem + nabPTX received a slow (over 30–40 min) intravenous infusion of
nab-paclitaxel (125 mg/m2) and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a
28-d cycle (every 4 wk). The dose of the chemotherapeutic agent was reduced and/or
administration  was  delayed  if  serious  treatment-related  adverse  events  (AEs)
occurred that made treatment intolerable. Chemotherapy was discontinued when life-
threatening AEs or disease progression was identified.
At the beginning of treatment, the following tumor-related factors were examined
and  recorded:  Patient  demographics,  patient  body  mass  index  (BMI),  date  of
diagnosis, tumor size and location, location and number of metastases, and laboratory
data including levels of carbohydrate antigen 19-9. To evaluate treatment efficacy,
computed tomography, magnetic resonance imaging, or 18F-fluorodeoxyglucose-
positron emission tomography was performed every 8 wk. All imaging studies were
conducted and reviewed according to institutional standard protocols. Treatment
responses according to the RECIST criteria were reported by designated radiologists
and final  disease assessments were independently performed by the responsible
physicians.
Assessment of treatment-related adverse events and drug costs
To monitor for treatment-related AEs, the presence of an AE was carefully examined
by physicians and registered nurses at each visit during chemotherapy. The category
and severity  grade  of  the  AEs  were  precisely  recorded in  the  patients’  medical
records. Treatment-related AEs were assessed and graded according to the National
Cancer Institute Common Terminology Criteria for Adverse Events version 4.0[14].
The anticancer drug cost that was actually paid by the patient was calculated based
on the  median body surface  area  (1.61  m2).  The total  cost  for  4  wk of  treatment
administration were compared between the two regimens, since each regimen had a
different administration protocol per cycle. Then, 4 d of hospital costs per cycle were
added  to  the  cost  of  FOLFIRINOX  because  these  patients  were  required  to  be
hospitalized  during  the  chemotherapy.  When  calculating  the  hospital  cost,  the
cheapest room covered by the Korean National Health Insurance Service (NHIS) was
used.
Study endpoints and statistical analysis
The primary endpoints were overall  survival  (OS) and progression-free survival
(PFS). The secondary endpoints were the rate and severity of treatment-related AEs.
OS was calculated as the date of diagnosis until the date of the most recent follow-up
or death. PFS was computed from the date of diagnosis to disease progression (or the
most recent follow-up or death). Object response was defined as complete response or
partial  response and disease control  was defined as complete response + partial
response and stable disease according to the RECIST criteria.
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All statistical analyses were performed using IBM SPSS Statistics for Windows,
version 23.0 (IBM Corp., Armonk, NY, United States), SAS version 9.4 (SAS Institute,
Cary,  NC,  United  States),  and  R  version  3.3.0  (The  R  Foundation  for  Statistical
Computing, Vienna, Austria). Baseline patient characteristics, laboratory data, and the
grade and frequency of AEs were used to calculate descriptive statistics. Student’s t-
tests were used to compare continuous variables and chi-square or Fisher’s exact tests
were used to compare categorical variables. Survival times and rates were estimated
using the Kaplan-Meier method (with log-rank test). Estimated medians with 95%
confidence intervals (CI) are reported. A Cox proportional-hazards model was used
for the subgroup analysis to estimate the hazard ratios for OS and PFS.
RESULTS
Patient characteristics
The baseline characteristics of all patients are presented in Table 1. The patients who
received FOLFIRINOX were significantly younger (54 vs 65 years; P < 0.001) and had
better performance status scores at baseline (proportion of ECOG-PS score 0: 83.7% vs
70.4%;  P  =  0.040)  than  those  who  received  Gem  +  nabPTX.  The  most  common
metastatic sites were the liver and peritoneum. Liver metastasis was more common in
the FOLFIRINOX group (66.3% vs 49.4%; P = 0.027) and peritoneal carcinomatosis
was more common in the Gem + nabPTX group (51.9% vs 40.7%; P = 0.148). There was
no difference in the number of metastasis sites between the two groups. In terms of
baseline laboratory data, a significantly higher neutrophil count was observed in the
FOLFIRINOX group. Other laboratory data, including carbohydrate antigen 19-9,
showed no differences between the two groups.
Treatment data and efficacy
The median follow-up period for all patients was 7.9 (range, 1.5–23.4) mo; during this
period,  78  (46.7%)  patients  died  and  101  (60.5%)  patients  experienced  disease
progression. The treatment data and efficacy of the two groups are presented in Table
2.  The  median  number  of  chemotherapy  cycles  received  by  each  patient  in  the
FOLFIRINOX and Gem + nabPTX groups was 8 and 5, respectively. There was no
statistically  significant  difference  in  the  median  duration  of  chemotherapy
(FOLFIRINOX, 138 d vs Gem + nabPTX, 154 d; P = 0.249). The median relative dose
intensities of gemcitabine and nab-paclitaxel were 93.3% and 86.2%, respectively. In
the FOLFIRINOX group, 80% of the planned dose of 5-FU and 75% of oxaliplatin and
irinotecan were administered to patients.
In aspect of efficacy, there was no statistically significant difference in the objective
response rate between the two groups (P = 0.082). However, the Gem + nabPTX group
showed a  significantly  higher  disease  control  rate  than the  FOLFIRINOX group
(84.0% vs 69.8%; P = 0.030). The median overall survival was 12.1 mo (95%CI, 10.7- not
estimable)  in  the  Gem  +  nabPTX  group  and  10.7  mo  (95%CI,  9.1–12.3)  in  the
FOLFIRINOX group (P = 0.157, Figure 1A). The median progression-free survival was
8.4 mo (95%CI, 5.0–11.8) in the Gem + nabPTX group and 8.0 mo (95%CI, 6.5–9.5) in
the FOLFIRINOX group (P = 0.134, Figure 1B).
Subgroup analysis
The treatment efficacy was consistently similar in both groups across the majority of
subgroups (Figure 2). In patients who had pancreatic body/tail cancer and a BMI >
23, the risk of death significantly reduced with the Gem + nabPTX regimen. Similar
trends were observed for PFS according to subgroup. In addition to primary cancer
site and BMI, the presence of liver metastasis and carcinomatosis at diagnosis were
associated with the hazard ratio of disease progression.
Treatment-related AEs
The treatment-related AEs observed in this study population are shown in Table 3.
Notable AEs occurred in both groups. In terms of haematologic AEs, the incidence of
severe (grade 3 or more) anemia and thrombocytopenia were similar between the two
groups. Both groups demonstrated a notable incidence of severe neutropenia, but the
FOLFIRINOX  group  showed  a  statistically  significantly  higher  rate  of  severe
neutropenia (74.4% vs 46.9%; P < 0.001). The granulocyte-colony stimulating factor (G-
CSF) administration rate was also significantly higher in the FOLFIRINOX group.
In the Gem + nabPTX group, more than half of the patients (46, 56.8%) showed
peripheral neuropathy and 15 (18.5%) developed severe peripheral neuropathy after
chemotherapy. On the other hand, the rate of neurologic AEs in the FOLFIRINOX
group was significantly lower. The median time to onset of peripheral neuropathy
was shorter in the Gem + nabPTX group, but not statistically significant (73.5 vs 120 d;
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Table 1  Baseline characteristics of all patients, n (%)
Characteristics FOLFIRINOX (n = 86) Gem + Nab-paclitaxel (n = 81) P value
Age (yr) 54 (30-78) 65 (42-79) < 0.001
Male sex 49 (57.0) 37 (45.7) 0.144
ECOG-PS 0.040
0 72 (83.7) 57 (70.4)
1 14 (16.3) 24 (29.6)
Body mass index 22.13 (16.49-31.63) 21.97 (16.11-29.59) 0.432
Tumor location1 0.398
Head and neck 40 (46.5) 32 (39.5)
Body and tail 46 (53.5) 48 (49.3)
Metastasis site
Liver 57 (66.3) 40 (49.4) 0.027
Lung 9 (10.5) 12 (14.8) 0.397
Bone 4 (4.7) 6 (7.4) 0.5262
Peritoneum (carcinomatosis) 35 (40.7) 42 (51.9) 0.148
Distant LN 33 (38.4) 28 (34.6) 0.610
Othersite (e.g. adrenal gland) 14 (16.3) 20 (24.7) 0.177
No. of metastasis site 0.726
1 site 39 (45.3) 38 (46.9)
2 sites 30 (34.9) 24 (29.6)
3 or more 17 (19.8) 19 (23.5)
Laboratory data (at diagnosis)
WBC count (cells/μL) 6765 (2830-21880) 6240 (2580-12240) 0.068
Neutrophil count (cells/μL) 4660 (1610-18930) 4045 (1410-8540) 0.035
Prothrombin time (INR) 1.01 (0.80-1.28) 1.00 (0.83-1.16) 0.176
Total bilirubin (mg/dL) 0.7 (0.2-13.5) 0.6 (0.2-23.4) 0.200
AST (IU/L) 24 (9-204) 22 (9-765) 0.286
ALT (IU/L) 27 (5-192) 17 (5-717) 0.117
Alkaline phosphatase (IU/L) 116 (43-957) 92 (37-2080) 0.798
CA 19-9 at diagnosis (U/mL) 585.3 (3.4-20000) 305.2 (0.6-20000) 0.678
1Except for one case that originated from an ectopic pancreas;
2Fisher's  exact  test.  Gem +  nabPTX:  Gemcitabine  plus  nab-paclitaxel;  ECOG-PS:  Eastern  Cooperative
Oncology  Group  performance  status;  LN:  Lymph  node;  WBC:  White  blood  cell;  AST:  Aspartate
aminotransferase; ALT: Alanine aminotransferase; CA: Carbohydrate antigen.
P = 0.051). In terms of other non-hematologic AEs, the incidences of nausea/vomiting
and severe gastrointestinal AEs were higher in the FOLFIRINOX group while the
incidence of dermatologic AEs was higher in the Gem + nabPTX group.
Compared to those observed in previous phase-III trials (PRODIGE4/ACCORD11
and  MPACT  population),  the  proportions  of  patients  who  experienced  severe
neutropenia and febrile neutropenia were higher in the present study, regardless of
the treatment regimen administered. In addition, a larger number of patients in the
FOLFIRINOX group showed severe anemia and nausea/vomiting compared to that
observed in previous trials, and the incidence of severe fatigue was more than 10%
higher in the Gem + nabPTX group when compared with the MPACT population.
(Supplemental Table 1).
Dose reduction, delay of administration and cessation of administration
Dose modification, treatment delay and cessation are shown in Table 4. Proportion of
patients who experienced dose reduction of chemotherapeutic agent was significantly
higher in FOLFIRINOX group patients than Gem + nabPTX group (88.4 % vs 60.5%; P
< 0.001). In the FOLFIRINOX group, most patients experienced dose reduction prior
to the 1st response evaluation (68 of 76 patients), whereas in the Gem + nabPTX group,
many patients experienced dose reduction after the 1st response evaluation (30 of 49
patients).
Among the FOLFIRINOX group, 47 (54.7%) patients experienced delayed treatment
and 12 (14.0%) patients discontinued chemotherapy due to adverse events. In the
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Table 2  Treatment data and efficacy of FOLFIRINOX and gemcitabine plus nab-paclitaxel, n (%)
FOLFIRINOX (n = 86) Gem + nabPTX (n = 81) P value
Duration of chemotherapy
Cycles 8 (2-24) 5 (2-16)













Best response of chemotherapy 0.067
Complete response 0 (0) 0 (0)
Partial response 29 (33.7) 38 (46.9)
Stable disease 31 (36.0) 30 (37.0)
Progression of disease 26 (30.2) 13 (16.0)
Response rates
Objective response rate 29 (33.7) 38 (46.9) 0.082
Disease control rate 60 (69.8) 68 (84.0) 0.03
Gem + nabPTX: Gemcitabine plus nab-paclitaxel.
Gem + nabPTX group, 51 (63.0%) and 17 (21.0%) patients experienced treatment delay
and discontinuation respectively. The proportion of treatment delay and cessation
were not statistically different between both groups.  The most common cause of
delayed treatment was hematologic AE, and general weakness was the most common
cause of early-termination of chemotherapy in both groups.
Drug costs
The anticancer drug cost was similar between the two groups. In patients treated with
the FOLFIRINOX regimen, the cost of 1 cycle, which lasted 2 wk, was determined to
be 52190 KRW. After adding the room charges, the total cost for 4 wk treatment of the
FOLFIRINOX regimen was 138724 KRW. The cost for 4 wk of the Gem + nabPTX
regimen was 168838 KRW. Drug costs of two regimens were not very different - only
30000 KRW (about 30 USD) per month.
DISCUSSION
In the present study, the oncologic outcomes of the FOLFIRINOX and Gem + nabPTX
regimens were found to be similar. Although the disease control rate was higher in
the Gem + nabPTX group, there was no significant difference in objective response
rate, OS, or PFS. In the subgroup analysis, Gem + nabPTX regimen showed survival
advantages in relation to the patients' baseline factors such as body/tail cancer, high
BMI, presence of liver metastasis and peritoneal carcinomatosis. When comparing the
two regimens in terms of safety, patients who received FOLFIRINOX were at higher
risk for the development of high-grade neutropenia, while those who received Gem +
nabPTX were at higher risk for neuropathy and fatigue.
Compared to previous clinical trial data, the treatment efficacy observed in this
study population was favourable.  Patients who received Gem + nabPTX showed
improved OS (12.1 vs 8.5 mo) and PFS (8.4 vs 5.5 mo) than those in the MPACT. The
FOLFIRINOX  group  patients  also  showed  improved  PFS  (8.0  vs  6.4  mo)  when
compared to those in the PRODIGE 4/ACCORD 11 trial, with similar OS rates (10.8 vs
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Figure 1
Figure 1  Overall survival and progression-free survival. A: Kaplan-Meier estimates of overall survival; B: Progression-free survival.
11.1 mo). On the basis of these data, we can consider that both the FOLFIRINOX and
Gem  +  nabPTX  regimens  are  very  effective  in  Korean  patients  with  metastatic
pancreatic cancer.
However, treatment-related AEs were more common in this study population than
in the previous clinical trials, especially hematologic AEs. Compared to the PRODIGE
4/ACCORD 11 trial[7] the FOLFIRINOX group patients in this study were younger
(median age, 54 vs  61 years) and had better performance status scores at baseline
(higher proportion of ECOG-PS score 0: 83.7% vs 37.4%). The median relative dose
intensity  of  each  agent  was  similar  (5-FU,  80% vs  82%;  oxaliplatin,  75% vs  78%;
irinotecan, 75% vs 81%). However, the rate of hematologic AEs was remarkably high
in this study population and similar to the proportion of hematologic AEs reported in
a previous Japanese phase-II study[15]. Considering that the PRODIGE 4/ACCORD 11
trial was conducted at 48 French medical centers and that the rates of AEs in the
Korean and Japanese population are similar, it can be assumed that there was an
ethnic difference in the incidence of treatment-related AEs using the FOLFIRINOX
regimen.
Ethnic  differences  in  terms  of  drug  efficacy  or  AEs  are  affected  by  local
environment, dietary habits, genetic mutations, and genetic polymorphism[12]. Ethnic
variations in polymorphisms can be an explanation for the racial differences in AEs.
For example, the UGT1A1 polymorphism, which is related with the glucuronidation
of SN-38 (an active metabolite of irinotecan) is associated with irinotecan-mediated
diarrhea  and  neutropenia [ 1 6 ].  UGT1A1  No.  6  mutations,  which  are  found
predominantly in Asian populations, have been implicated in irinotecan toxicity[16-19].
Goetz  et  al[20]  recommended  UGT1A1  genotype-guided  dosing  of  CAPIRINOX
(capecitabine, oxaliplatin, and irinotecan) in their phase I study because the toxicity
profile differed according to the presence of UGT1A1 polymorphisms. Defective
cytochrome P450 3A4 (CYP3A4) variants are another example known to be related
with paclitaxel-induced neuropathy[21,22]. Although direct associations with different
pharmacokinetics  according  to  ethnicity  has  not  yet  been  established,  ethnic
differences in the frequency of polymorphisms of CYP3A4 have been reported[23].
Both regimens carry an unfavourable AE profile;  therefore,  dose modification
strategies have been made. In terms of the FOLFIRINOX regimen, several studies
used modified (reduced) doses through various methods to increase the patients’
tolerance.  For  example,  Mahaseth et  al[24]  replaced the  5-FU bolus  injection with
haematopoietic  growth  factors.  Stein  et  al[25]  used  a  modified  dose  with  a  25%
reduction  in  both  irinotecan  and  the  5-FU  bolus.  Li  et  al [26]  used  modified
FOLFIRINOX  (no  5-FU  bolus,  85%  oxaliplatin,  and  75%  irinotecan)  in  Chinese
patients with metastatic pancreatic cancer. In their studies, the incidence of severe
neutropenia,  fatigue,  and  vomiting  were  reduced,  without  any  compromise  in
treatment efficacy. Ahn et al[27] presented a modified biweekly Gem + nabPTX regimen
that  could  reduce  the  incidence  of  severe  neutropenia  and  neurotoxicity  when
compared with that reported in the MPACT data[27].
In our study population, 43 patients (50% of FOLFIRINOX group) started receiving
the FOLFIRINOX regimen as a modified (reduced) dose. There was no significant
difference in treatment duration and efficacy. Moreover, no significant difference was
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Figure 2
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Figure 2  The treatment efficacy was consistently similar in both groups across the majority of subgroups. A: Forest plots of hazard ratio for overall survival;
B: Progression-free survival according to subgroups.
noted in the incidence of non-hematologic AEs. However, the incidences of severe
(grade ≥ 3) neutropenia and febrile neutropenia were lower in patients who received
the modified dose than in those who received the full dose (severe neutropenia, 62.8%
vs 86.0%; P = 0.013, febrile neutropenia, 18.6% vs 32.6%; P = 0.138). It may be helpful
to use a modified dose when initiating chemotherapy for toxicity-susceptible patients
identified via early screening tests.
Second-line chemotherapy could be considered after first-line therapy failure if
patients continue to demonstrate good performance status. Even after a failure of
first-line treatment, effective second-line chemotherapy can prolong patients’ post-
progression  survival  (PPS,  overall  survival  from  the  notification  of  disease
progression) and OS[28,29]. In this study population, 20 (24.7%) patients in the Gem +
nabPTX  group  and  38  (44.2%)  in  the  FOLFIRINOX  group  received  second-line
chemotherapy.  XELOX  (capecitabine  plus  oxaliplatin)  was  the  most  commonly
prescribed second-line regimen in the Gem + nabPTX group and gemcitabine plus
erlotinib  was  the  most  common  second-line  treatment  administered  in  the
FOLFIRINOX group. No difference in PPS was noted between the two groups (Gem +
nabPTX group, 136 d [95%CI, 78.384–193.616]; FOLFIRINOX group, 148 d [95%CI,
120.576–175.424]; P = 0.762). Overall, patients who received second-line chemotherapy
showed a significantly longer PPS than patients who did not (138 vs 39 d; P < 0.001) In
particular, second-line chemotherapy was found to be more effective in patients who
showed early progression within 3 mo after the first-line treatment (median PPS, 153
d). Recently, several studies have been conducted to assess the efficacy of second-line
chemotherapy. Portal et al[30] showed that second-line Gem + nabPTX was effective
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Table 3  Treatment-related adverse events due to the chemotherapy regimen, n (%)
FOLFIRINOX (n = 86) Gem + nabPTX (n = 81) P value
Hematologic adverse event
Grade ≥ 3 Anemia 17 (19.8) 12 (14.8) 0.398
Grade ≥ 3 Thrombocytopenia 7 (8.1) 5 (6.2) 0.623
Grade ≥ 3 Neutropenia 64 (74.4) 38 (46.9) < 0.001
Febrile neutropenia 22 (25.6) 13 (16.0) 0.130
Administration of G-CSF 66 (76.7) 15 (18.5) < 0.001
Neurologic adverse event
Peripheral neuropathy 16 (18.6) 46 (56.8) < 0.001
Grade ≥ 3 neuropathy 3 (3.5) 15 (18.5) 0.002
Median time to onset-days (range) 120 (15-278) 73.5 (17-284) 0.051
Gastrointestinal adverse event
Nausea/Vomiting 43 (50.0) 17 (21.0) < 0.001
Diarrhea 15 (17.4) 12 (14.8) 0.645
Grade ≥ 3 adverse events 39 (45.3) 16 (19.8) < 0.001
General weakness 30 (34.9) 40 (49.4) 0.058
Dermatologic adverse event 12 (14.0) 34 (42.0) < 0.001
G-CSF, granulocyte-colony stimulating factor; Gem + nabPTX: Gemcitabine plus nab-paclitaxel.
after  the  failure  of  first-line  FOLFIRINOX[30].  The  NAPOLI-1  trial  revealed  that
nanoliposomal irinotecan (nan-IRI) plus 5-FU was effective in patients previously
treated with gemcitabine-based chemotherapy[31]. Another clinical trial showed that
oxaliplatin, folinic acid, and fluorouracil (OFF regimen) was effective in gemcitabine-
refractory pancreatic cancer patients[32]. Furthermore, there are ongoing studies testing
FOLFIRINOX after Gem + nabPTX failure[33].
As more options for second-line chemotherapy are being introduced, questions
surrounding treatment choice and sequence have arisen. The advantage of using
FOLFIRINOX as a first-line regimen is that Gem + nabPTX, which has similar efficacy,
can be used as the secondary drug. On the other hand, patients who receive Gem +
nabPTX as the first-line drug can choose diverse 5-FU based regimens (i.e. OFF, nal-
IRI  +  5-FU,  or  FOLFIRINOX)  as  second-line  treatment  depending  on  their
performance status. Although more favourable sequences need to be studied, the
active use of FOLFIRINOX or Gem + nabPTX as a second-line regimen or appropriate
use of new agents such as nal-IRI may help to improve the prognosis of patients who
show early progression.
When  we  consider  the  economic  aspects  of  anticancer  treatment,  we  have  to
consider  both  anticancer  drug  costs  and  general  management  costs  such  as
hospitalization  or  medication  fees  for  AE  control.  Gemcitabine,  nab-paclitaxel,
oxaliplatin,  and irinotecan are expensive drugs.  Fortunately,  in Korea,  the NHIS
provides economic benefits for cancer patients-the NHIS provides 95% of the drug
cost. Therefore, when NHIS coverage for cancer patients is reflected, the costs of the
two regimens (per month) are similar. However, in terms of potential cost burden, the
FOLFIRINOX  regimen  seems  to  have  some  disadvantages.  Patients  must  be
hospitalized to receive the FOLFIRINOX regimen. During hospitalization, additional
costs that are not covered by the NHIS, such as private rooms, can occur. In addition,
due to the higher hematologic AE rates, the cost for prolonged hospitalization, G-CSF
administration, and infection control (related to febrile neutropenia) are more likely to
occur in patients receiving FOLFIRINOX. However, for a more accurate comparison,
additional  quantitative  and comparative  analysis  is  also  needed in  terms of  the
decreased labour productivity or quality of life due to admission or severe AEs such
as peripheral neuropathy, fatigue, or alopecia[34,35].
This  study  had  several  limitations.  First,  it  was  a  retrospective  cohort  study
conducted only in a single center. A prospective randomized controlled trial is needed
to  confirm  and  validate  the  results  of  this  study.  And,  to  determine  the  ethnic
differences in efficacy and safety more clearly, a larger scale nation-wide study will be
helpful. Second, this study did not quantify the change in the quality of life. There
was a lack of medical records and questionnaires that could help to more precisely
analyse quality of life. Finally, we could not perform more advanced genetic analyses.
If new technologies (e.g.,  next-generation sequencing) are actively used in clinical
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Table 4  Dose modification, treatment delay and cessation, n (%)
Variables FOLFIRINOX (n = 86) Gem + nabPTX (n = 81) P value
Dose reduction 76 (88.4) 49 (60.5) < 0.001
At beginning 43 (50) 7 (8.6)
Before 1st RE 25 (29.1) 12 (14.8)
1st RE-2nd RE 5 (5.8) 15 (18.5)
After 2nd RE 3 (3.5) 15 (18.5)
Delay of administration due to AE 47 (54.7) 51 (63.0) 0.346
Neurologic AE 2 (2.4) 14 (17.3)
Hematologic AE 30 (34.9) 22 (27.2)
Gastrointestinal AE 3 (3.5) 4 (4.9)
General weakness 8 (9.3) 20 (24.7)
Others 6 (7.0) 2 (2.5)
Cessation of administration due to AE 12 (14.0) 17 (21.0) 0.307
Neurologic AE 2 (2.4) 3 (3.7)
Hematologic AE 1 (1.2) 0 (0)
Gastrointestinal AE 1 (1.2) 2 (2.5)
General weakness 8 (9.3) 11 (13.6)
Death 0 (0) 1 (1.2)
RE: Response evaluation; AE: Adverse event; Gem + nabPTX: Gemcitabine plus nab-paclitaxel.
fields, it will be possible to collect and analyse genetic data more economically and
easily.
The results of the present study suggest that the FOLFIRINOX and Gem + nabPTX
regimens are  similar  in  efficacy,  but  the type and rates  of  the AE are somewhat
different:  neurologic  AEs  were  more  common in  the  Gem + nabPTX group and
hematologic AEs were more common in the FOLFIRINOX group. Given the subgroup
analysis of this study, Gem + nabPTX regimen could be considered as a priority in
patients with specific baseline conditions.
ARTICLE HIGHLIGHTS
Research background
FOLFIRINOX regimen and combination of gemcitabine and nab-paclitaxel (Gem + nabPTX) are
recommended as the first-line therapy for metastatic pancreatic cancer. However, there is a lack
of data regarding a direct comparison of the two regimens in efficacy and safety.
Research motivation
When treating metastatic pancreatic cancer patients, physicians would like to select appropriate
chemotherapeutic regimens while avoiding and preventing unnecessary complications and
economic burdens. By comparing the efficacy and safety of two regimens, this study can help
physicians’ decision of treatment choice and sequence.
Research objectives
The  purpose  of  this  study  is  to  compare  the  efficacy,  safety,  and  economic  aspects  of
FOLFIRINOX and Gem + nabPTX in the treatment of metastatic pancreatic cancer in Korean
population.
Research methods
Patients with metastatic or recurrent pancreatic cancer treated with FOLFIRINOX (n = 86) or
Gem + nabPTX (n = 81) as the first-line since January 2015 were identified using the Severance
Hospital  Pancreatic  Cancer Cohort  Registry.  Treatment efficacy,  treatment-related adverse
events and economic aspects were compared.
Research results
The  median  overall  survival  (FOLFIRINOX  10.7  vs  Gem  +  nabPTX  12.1  mo;  P  =  0.157),
progression-free survival (FOLFIRINOX 8.0 vs Gem + nabPTX 8.4 mo; P = 0.134), and objective
response rates (FOLFIRINOX 33.7% vs Gem + nabPTX 46.9%; P = 0.067) were not significantly
different between two regimens. Neurologic adverse events were more common in the Gem +
nabPTX group and Grade ≥  3  neutropenia  and gastrointestinal  adverse  events  were  more
common in the FOLFIRINOX group. The drug costs of both regimens were similar.
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Research conclusions
Treatment efficacy and economic burdens were comparable between the two regimens. But, the
type and rates of the adverse events were somewhat different. Given the subgroup analysis of
this study, Gem + nabPTX regimen might be considered preferentially in patients with specific
baseline conditions.
Research perspectives
This study will help clinicians choose an appropriate chemotherapeutic regimen for metastatic
pancreatic cancer. To confirm and validate the results of this study, a larger scale prospective
study would be helpful.
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